Germinal center subtype of Diffuse Large B Cell Lymphoma
Conditions
Interventions
one :Chidamide with Rituximab
Sponsors
Qilu Hospital, Shandong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Diffused large B cell lymphoma diagnosed with pathological evidence, and verified to be GCB subtype with immunohistochemistry, refractory DLBCL means cases that are non-responsive or even with progression after 2 standard course of CHOP with/without Rituximab; relapsed DBLCL is diagnosed with the criteria in Appendix 1; (2) Aged 18-75 years old; (3) KPS>80 (4) Expected overall survival> 3 months; (5) Clinically measurable or accessible foci should present, measurable foci are defined as foci that are clear in imaging examination with measurable double diameters (>=1cm×1cm on CT or MRI, >=2cm×2cm in physical examination or ultrasonography), accessible foci are defined as foci that only have single measurable diameter; (6) The value of biomarkers of hepatic and renal function (like bilirubinserum creatinin) is under twice of the normal value; (7) Heart function: no obvious or uncontrollable heart disease, no myocardial infarction in the past 6 months, no obvious congestive heart failure, no obvious supra-ventricular or ventricular arrhythmias, no grade II or III conduction block, no acute myocardial ischemia or QT interval elongation; (8) Pulmonary function: no uncontrollable pulmonary function disorder; (9) Patients must sign the written consent before inclusion and they should be able to implement the consent physiologically and emotionally.
Exclusion criteria
Exclusion criteria: (1) With active infection; (2) With metastatic brain diseasesevere brain disease or mental disorders that can influence the patients private prosecution; (3) With other malignant tumors that have not been effectively controlled; (4) Women in pregnancy or lactation, and those with fertility but are not willing to employ effective contraceptives or their spouses are not willing to employ effective contraceptives; (5) Has taken part in other clinical trials within the past 4 weeks; (6) With thrombosis history; (7) With other conditions that the researchers think are not appropriate for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imagine (tumor size);tumor marker; | — |
Secondary
| Measure | Time frame |
|---|---|
| history;physical examination;Blood routine test; | — |
Countries
China
Contacts
Public ContactMing Hou
Departments of Hematology, Qilu hospital, Shandong University
Outcome results
None listed